Tybar TCV is the world’s first clinically proven typhoid vaccine (TCV) manufactured by Bharat biotech , designed to prevent typhoid fever caused by salmonella Typhi bacteria. It works by conjugating vi capsular polysaccharide with tetanus Toxoid , creating a strong T-dependent immune response that is effective for all age groups, including infants from 6 months of age. It is particularly critical as it is the only approved vaccine for children under 2 years of age and offers protection against antibiotic-resistant strains of typhoid .

Vaccination is critical tool for preventing typhoid fever , a life –threathning bacterial infection that affects approximately 9 million people and causes 110,000 deaths annually , according to WHO estimates . it’s importance has grown significantly due to the rise of extensively drug –resistance (XDR) strains that make traditional antibiotic treatment less effective.

WHAT IS TYBAR –TCV?

Tybar –TCV is a typhoid conjugate vaccine (TCV) developed by bharat biotech , classified as an active immunization agent designed to prevent typhoid fever . it is a T-cell-dependent vaccine containing the purified Vi capsular polysachride of salmonella typhi conjugated to a tetanus toxoid carrier protein ,suitable for infants , children and adults.

Key classification :

 Type: conjugate vaccine (polysaccharide conjugated to tetanus Toxoid )
· Classification : Active immunizing Agent
· Target: salmonella enterica serovar typhi (Ty2)
· Mechanism: T-cell dependent, providing higher-affinity antibodies and long –term immune memory .
· Dose & Administration : single 0.5 ml dose via intramuscular injection.
· Age Range : indicated for infants, children and adults from 6 months up to 65 years .
· Who status: WHO –prequalified
· Efficacy: studies shows high effectiveness in children (e.g 81.6% in a Nepal )

WHICH DISEASE IS PREVENTED BY TYBAR –TCV VACCINE?
Disease prevented by TYBAR –TCV vaccine are:
TYPHIOD FEVER
Tybar TCV vaccine is a highly effective ,single-dose vaccine that prevents typhoid fever by inducing a strong immune response in adults, children and infants 6 months and older. It has demonstrated 81.6% to 100 % efficacy in clinical trails and is recommended by the WHO for preventing typhoid, including in endemic regions. Studies have shown it prevents a significant majority of typhoid cases , with reported efficacy rates of 81.6% in Nepal and 87.1% in a human challenging study. Approved for use in children from 6 months of age , as well as adults up to 45 years. It is a conjugate vaccine that uses the purified vi capsular polysaccharide of salmonella typhi conjugated to a tetanus toxoid carrier protein , creating long-term immunity. It provides long lasting protection ,reducing the need for frequent booster doses compared to older vaccines.

DOSAGE & ADMINISTRATION

Typbar –TCV is a typhoid conjugate vaccine manufactured by Bharat Biotech that helps prevent typhoid fever in individuals .

Administration method: intramuscular (1M) injection only, typically in the deltoid muscle or the anterolateral aspect of the thigh, depending on the age.
· Target population : approved for use in individuals from 6 months to 45 years of age.
· Vaccination schedule : it is administered as a single injection .
· Boosters: recommendation for booster doses may be considered for individuals who remain at risk, based on guidance from health authorities.
· Timing: vaccination is recommended prior to potential exposure .

WHAT ARE THE BENEFITS OF TYBAR-TCV INJECTION? 

1. Provides long lasting immunity
Typar TCV provides long- lasting immunity against typhoid fever ,with studies demonstrating high efficacy and persistent antibody levels for several years . A single 0.5 ml dose is generally sufficient to offer lasting protection in adults and children over 6 months old. Studies show protective, high antibody levels persist up to 7 years post –vaccination. A single dose elicited 92-99% seroconversions rates across various age groups . as a conjugated vaccine ,it offers longer-lasting protection compared to older, unconjugated vi polysaccharide vaccines ,which requires boosters every three years .

2.EFECTIVE IN YOUNG CHILDREN 
Typbar TCV is highly effective and safe for young children, including infants from 6 months of age. It is the first typhoid vaccine approved for children under 2, providing over 80% protection with a single dose, making it crucial for protecting toddlers who are highly susceptible to typhoid. Studies show tybar TCV prevents 79% to 85% of typhoid cases in children. It is approved for children of 6 months and older, with proven efficacy in children younger than 2 years . A single dose offers durable protection for at least 4 years . it is safe to co-administer with other routine childhood vaccines including measles –rubella.
3. Reduced the risk of Typhoid infection
Tybar TCV is a highly effective ,single-dose vaccine that significantly reduces the risk of typhoid infection, including against drug-resistant strains. It is recommended for children from 6 months of age, with studies showing 80 %-90% efficacy in high-burden ,endemic regions. Studies shows it provides provides robust protection ,with one study indicating 81-85% efficacy in children . it provides longer lasting immunity compared to older vaccines ,with studies showing protection lasting up to 3-5 years or more.
WHAT ARE THE POSSIBLE SIDE EFFECTS OF TYBAR_TCV INJECTION?
 
Possible side effects of TYbar –TCV injection are:

1. Pain or swealling at injection site
2. Mild fewer
3. Fatigue
4. Headache
5. Rare allergic reactions

CONCLUSION
Tybar Tcv is concluded to be a highly effective, safe and durable single-dose vaccine for children (from 0 to 6 months ) and adults, providing over 80-90 % protection against typhoid fever. It offers superior, longer-lasting immunity compared to older polysachride vaccines , maintaining high antibody titters for years.

FREQUENTLY ASKED QUESTIONS (FAQs):

QUESTION: AT WHAT AGE CAN TYPBAR –TCV BE GIVEN?

Tybar TCV is approved for administration to infants, children and adults , with eligibility starting at 6 months of age ,upto 45 years . it is commonly given as a primary vaccination during infancy or as a booster for older children . it is administred as a single intramuscular dose.

QUESTION: HOW LONG DOES PROTECTION LAST?
A single dose of TYpbar TCV provides protection against typhoid fever for at least 3 to 4 years in adults, children and infants over 6 months of age. Studies suggest it provides strong, long-lasting emptiness with some evidence showing peristant cold frame upto 7 years post-vaccination ,though a booster may be considered around 5 years.

QUESTION: IS A BOOSTER DOSE REQUIRED?
Tybar TCV is typically administred as a single dose for individuals aged 6 months to 45 years. While it provides long-term dismantelment guidelines for booster doses may vary based on regional health recommendations and individual risk factors.

REFRENCES:

1)https://www.1mg.com/drugs/typbar-tcv-vaccine-294114?srsltid=AfmBOookfAoC2kbqVHxf0p9EfHxtW5nC_zg3DMsoURl9e2csKNwhsil3&wpsrc=Google+Organic+Search

2)https://www.apollopharmacy.in/medicine/typbar-tcv-pfs-injection-0-5ml?srsltid=AfmBOooUvxxtQc1JJGqr2hmzFZdFxCRlDFY6vW5WbyxhhNWwkJdWIs9P